News
We send the latest information from SMC Laboratories.
SMC announces Announcement of webinar 【High quality non-clinical study designs】
Today we are excited to invite you to join our Online Linkedin Webinar that will be taking place next week on …
NASH, the fastest growing cause of liver cancer
We wish you a Happy and Prosperous New Year! If you are currently planning to begin a project this year, we wo…
SMC to attend Japan-UK Virtual Partnering!
We are pleased to announce that SMC Laboratories will be participating in the Japan-UK Virtual Partnering Onli…
Fibrosis is involved in many diseases and disease-related deaths
Today's topic is Fibrosis. We would like to discuss with you the importance of therapeutic treatments tha…
Study on the efficacy of dietary supplements in the STAM™ model published in Cell Death & Disease.
SMC is proud to announce that J2H biotech (KOR) has published the results of their study using our pre-clinica…
Introduction of STAM™ model for pre-clinical studies for liver cancer
Today, we give you a brief introduction to our proprietary NASH-HCC model (STAM™ model). The STAM™…
Study on the efficacy of dietary supplements in the STAM™ model published in BMJ Open Gastroenterology
SMC is proud to announce that GN Corporation Co. Ltd (JPN) has published the results of their study using our …
Drug Efficacy Study in the STAM™ Model Published in Biomedicines.
SMC is proud to announce that MRM Health (BEL) has published the results of their study using our STAM™ …
Introducing our new skin disease model: Imiquimod (IMQ)-induced psoriasis model
We are pleased to announce that we have expanded our preclinical model lineup by including the “Imiquimo…
Introduction of MAFLD criteria and the disease model
Today, we would like to introduce metabolic dysfunction-associated fatty liver disease (MAFLD), a new concept …